最新临床试验：帕博利珠单抗与标准护理观察治疗完全切除I-III期默克尔细胞癌患者的对比

这是经美国国家癌症研究所批准的一项多中心随机对照 III期临床试验，目的是研究与标准护理观察相比，帕博利珠单抗在治疗已通过手术完全切除的I-III期默克尔细胞癌患者方面的疗效。用单克隆抗体（如帕博利珠单抗）进行免疫治疗可能有助于机体免疫系统攻击癌症，并可能干扰肿瘤细胞生长和扩散的能力。

该临床试验在全美181家医院进行开展。

This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Trial IDs